secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060243
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS
--------------------------------------------------------------------------------

- CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.
- SNOT-22 improvement maintained at Week 28: -17.6 points (p=0.007) vs sham.
- Cash, equivalents and investments $102.6M, sufficient into Q1 2025.
- ENLIGHTEN I Phase 3 fully enrolled; topline results expected 1H 2024.
- Net loss $15.7M vs $14.8M year-over-year; R&D spend up to $12.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/0000950170-23-060243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/lyra-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer